Chimeric Antigen Receptor-Modified T Cell Immunotherapy for Relapsed and Refractory Adult Burkitt Lymphoma

Patients with Burkitt lymphoma who are refractory to initial therapy or who relapse after undergoing intensive chemotherapy and autologous stem cell transplantation (ASCT) usually have a poor prognosis. While there has been considerable progress in the use of chimeric antigen receptor-modified (CAR)...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Jiaying, Cao, Yang, Zhang, Qi, Liu, Wanying, Zhou, Xiaoxi, Ming, Xi, Meng, Fankai, Zhang, Yicheng, Li, Chunrui, Huang, Liang, Wei, Jia, Zheng, Miao, Zhang, Shangkun, Zhang, Tongcun, Zhu, Xiaojian, Wang, Na, Wang, Jue, Wang, Gaoxiang, Zhou, Jianfeng, Liu, Bo, Xiao, Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164136/
https://www.ncbi.nlm.nih.gov/pubmed/35669773
http://dx.doi.org/10.3389/fimmu.2022.879983

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164136/
https://www.ncbi.nlm.nih.gov/pubmed/35669773
http://dx.doi.org/10.3389/fimmu.2022.879983

Ejemplares similares